晚期非小细胞肺癌个体化治疗资料.pptxVIP

晚期非小细胞肺癌个体化治疗;个体化治疗;影响药物敏感性的因素;Prognosticversuspredictivebiomarkers:theyarenotalwaysthesame;Factorsusedtoindividualizedcancertreatment;;FirstlinegefitinibforpoorPSpatientswithEGFRmutations;Efficacy;DNA修复基因的SNP;;SurvivalinDoc/CistreatedstageIVNSCLCptswithPS0accordingtoERCC1C8092ASNP;XRCC1和XPDSNP与含铂方案疗效之间的关系;Factorsusedtoindividualizedcancertreatment

102例未治疗过晚期NSCLC,接受Ｄ/G一线化疗

-208个基因的5438个SNP－－药物转运/代谢

Roselletal.

Roselletal.

PhaseIIIPCvsGCTrial:StudyDesign

-蛋白表达(IHC,蛋白组学)

PNA－LNA－PCR方法

041)低BRCA1+高RRM2(32例）

Non-inf

margin

(1.

-依赖于精确诊断方法和靶向治疗;GeneticpolymorphismscorrelatewithOSinadvancedNSCLCtreatedwithtaxol/carbo;;

PredictiveeffectsofERCC1andXRCC3SNPonefficacyofplatinum-basedchemotherapyinadvancednon-smallcelllungcancerpatients

;ThepatientswithERCC1118C/TorT/Tgotbettersurvivalbenefitfromplatinum-basedchemotherapy;PhaseIIIPCvsGCTrial:StudyDesign;;ERCC1既是预后因子，又是含铂方案化疗的受益预测因子;PhaseIIIstudyofERCC1guidedtreatmentinadvancedNSCLC;Customizingplatinumchemotherapy:responsebyERCC1profiling;;ProspectiveevaluationofRRM1asapredictorofresponsetogem/carboinNSCLC;;;MADeIT;BRCA1mRNAinGem/Cis-Treated

StageIIIAN2NSCLC;;SLA-TrialofcustomizedtreatmentbasedonEGFRmutationsandBRCA1mRNAexpression:ancillaryanalysisofAbraxaxandRAP90expression;;;肿瘤组织BRCA1,RRM1和RRM2mRNA表达与多烯紫杉醇/吉西他滨一线晚期NSCLC的疗效;Responseingem/doc-treatedstageIVNSCLCaccordingtoBRCA1mRNAlevels;TTPtosecondlinecisplatininfirst-linegem/doctreatedstageIVNSCLCaccordingtoBRCA1levels;;;;;-其它基因SNP的作用？

102例未治疗过晚期NSCLC,接受Ｄ/G一线化疗

-不是剥夺病人治疗机会，而是，增加治疗成功率

FirstlinegefitinibforpoorPSpatientswithEGFRmutations

Roselletal.

SLA-TrialofcustomizedtreatmentbasedonEGFRmutationsandBRCA1mRNAexpression:ancillaryanalysisofAbraxaxandRAP90expression

-涉及到寻找基因，基因组，和临床信息：准确地预测疾病

PredictiveeffectsofERCC1andXRCC3SNPonefficacy